Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Alert: ImmunityBio Surges on November 18 Due to ANKTIVA Data, FDA Submission, and Bladder Cancer Progress

US Stock Alert: ImmunityBio Surges on November 18 Due to ANKTIVA Data, FDA Submission, and Bladder Cancer Progress

Bitget异动解读Bitget异动解读2026/11/18 17:34
Show original

ImmunityBio November 18 Surge Interpretation

Keywords: ANKTIVA data, FDA application, bladder cancer

1. On November 17, the company CEO disclosed at an investor conference in London that the p-value for the six-month results of ANKTIVA combined with BCG in treating bladder cancer was 0.01. In the trial of 370 cases, more patients showed no detectable cancer. The company plans to submit an application to the FDA within weeks for use in patients' first BCG treatment cycle.

2. On November 9, the company announced that ANKTIVA combined with BCG achieved the primary endpoint in the BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial, cohort A. The company is an immunotherapy business at the commercialization stage, with its core product ANKTIVA being an IL-15 receptor superagonist. It is leveraging the Cancer BioShield platform to develop next-generation immunotherapies.

(Disclaimer: This content is a summary of publicly available information collected and generated by AI technology, for reference only and does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!